Suraksha Diagnostics IPO: Public Issue Fully Subscribed On Final Day, GMP Flat; Check Key Dates & More

Suraksha Diagnostics Limited's initial public offering (IPO) has entered its final day of subscription, offering investors a last chance to participate in this Rs 846.25 crore public issue. The IPO, which opened on Friday, November 29, 2024, is entirely an Offer for Sale (OFS), meaning the proceeds will go to the selling shareholders, not the company. The price band for the IPO is set at Rs 420 to Rs 441 per equity share, with a minimum application size of 34 shares per lot.

Subscription Status

As of 3:06 pm on Day 3 of bidding, the Suraksha Diagnostics IPO has been subscribed 1.01 times, reflecting lukewarm investor interest. The Qualified Institutional Buyers (QIB) portion received relatively strong support, with a subscription of 1.52 times. However, the retail category and Non-Institutional Investor (NII) segment saw weaker demand, being subscribed 0.77 times and 0.91 times, respectively.

In the grey market, Suraksha Diagnostics shares are trading at par, neither commanding a premium nor a discount. This subdued grey market performance reflects cautious investor sentiment amid market volatility.

IPO Details

Suraksha Diagnostics' Rs 846.25 crore IPO is fully structured as an OFS, involving the sale of up to 19,189,330 equity shares by existing stakeholders, including promoters and investors such as OrbiMed Asia II Mauritius Limited and the Kejriwal family. ICICI Securities, Nuvama Wealth Management, and SBI Capital Markets are the book-running lead managers, while Kfin Technologies is the registrar for the issue.

Key post-IPO dates include the finalization of share allotment on December 4, refunds and share crediting to demat accounts on December 5, and the anticipated listing on NSE and BSE on December 6.

Company Overview

Suraksha Diagnostics, a leading medical consultancy services provider, operates a robust hub-and-spoke model with one central reference lab, eight satellite labs, and 215 customer touchpoints across West Bengal, Bihar, Assam, and Meghalaya. Its network includes 49 diagnostic centres and 166 sample collection centres.

In terms of financial performance, the company has demonstrated significant growth. Between FY23 and FY24, Suraksha Diagnostics reported a 14.75% increase in revenue and a 281.32% rise in profit after tax (PAT). In Q1 FY25 alone, it conducted 1.58 million tests for approximately 2,80,000 patients.

Suraksha Diagnostics operates in a highly competitive diagnostics market, facing established players such as Dr Lal PathLabs, Metropolis Healthcare, Thyrocare, and Vijaya Diagnostic. The company's focus on East India has helped establish strong regional dominance, with 95.34% of its revenue coming from this area. However, this geographical concentration also raises concerns about limited market diversification.

Peer comparison reveals Suraksha Diagnostics' potential and challenges. Competitors in the sector maintain high price-to-earnings (P/E) ratios, such as Dr Lal PathLabs at 77.08, Metropolis Healthcare at 89.61, Thyrocare at 65.52, and Vijaya Diagnostic at 86.40. While Suraksha Diagnostics' rapid growth trajectory offers promise, the subdued IPO subscription figures and grey market performance highlight investor caution.

Growth Potential and Risks

The company's hub-and-spoke model positions it for scalability, with plans to expand its services and enhance operational efficiencies. Proceeds from the IPO will facilitate its listing benefits but do not directly support business expansion, as the issue is solely an OFS. This structure has contributed to the tepid investor response.

Additionally, Suraksha Diagnostics' dependence on East India markets could pose risks in the long term, should regional competition intensify or economic conditions shift unfavourably.